Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Celltech buys Cistron for $18 million

Celltech (LSE:CCH; CLL) will use its ADSs

Read the full 76 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE